NCT06318416RecruitingPhase 1
Precision Rifampin Trial for Personalized Dosing
Precision Rifampin (P-RIF) Trial for Personalized Dosing in Active Tuberculosis Disease
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
Individual pharmacokinetic variability is an important driver of tuberculosis (TB) treatment failure particularly among undernourished populations, and that suboptimal serum drug concentrations are associated with delayed response to treatment, death, and acquired bacterial drug resistance. Serum drug exposures can be approximated by urine excretion as measured by spectrophotometry, replacing the need for specialized equipment for serum testing. Anti-TB pharmacokinetic variability has also been associated with enteric pathogen burden. The overall hypothesis is that urine spectrophotometry will identify people with below-target rifampin serum concentrations, which can be corrected to target levels after dose adjustment as confirmed by serum mass spectrometry. Therefore, this protocol includes a clinical trial to assess efficacy and safety of rifampin dose adjustment based on urinary excretion levels among adults and children who are being treated for drug-sensitive pulmonary TB at our longstanding collaborative research site in Haydom Lutheran Hospital, Tanzania.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 12 Mar 2024
- Start date
- 1 Oct 2025
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- University of Virginia
- Diseases
- Tuberculosis
- NCT number
- NCT06318416
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 200
- From 1 Oct 2025 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy: Urine rifampin spectrophotometry has not been studied in pregnant people, higher dose rifampin also less studied in pregnancy, and may confound potential toxicity signals (e.g. elevated liver function tests in pregnancy). Urine pregnancy test will be completed at screening in people of child-bearing potential. Child-bearing potential is defined as a person able to menstruate (menstruation in the last 12 months) and not receiving a form of contraception with less than \<1% failure rate (oral levonorgestrel, IUD or etonogestrel implant).
- Current treatment with a drug known to have significant interaction with anti-TB therapy
Lab values
- Oliguria: may complicate urine collection and limit correlation of urinary excretion and serum concentrations
- Kidney disease, defined as a glomerular filtration rate (GFR) \< 60 mL/min: In 5R01 AI137080, those adults with GFR \< 60 mL/min had reduced correlation or urinary rifampin excretion and serum concentrations.
- Severe anemia, defined as a hemoglobin level less than 7 g/dL: given planned phlebotomy
- Elevated liver function tests, defined as DAIDS grade 3 or above (ALT or AST \>/= 5 x upper limit of normal): may confound potential toxicity signals of dose adjustment strategy
Other
- Urinary incontinence: may complicate urine collection
- Weight \<10.0 kg (dose increase may exceed 30mg/kg/dose)
- Excessive alcohol use? (for example, Men consuming \> 14 standardized drinks per week and/or \> 4 drinks per day OR women consuming \>7 standardized drinks per week, and/or \>3 drinks per day, or at the discretion of the investigator(s).
Who the study is looking for
- Age 3 or older
- Diagnosed with active, rifampin-susceptible, pulmonary TB- sputum positive for M. tuberculosis complex without rpoB mutation, or culture for M. tuberculosis with conventional rifampin susceptibility OR among children unable to expectorate, meeting confirmed or probable consensus clinical case definitions for intrathoracic childhood TB
- Initiating combination anti-TB therapy with isoniazid, rifampin, pyrazinamide, and ethambutol
- Subject or guardian is able to provide informed consent; and for children 7 years or older, provide assent
- Stated willingness to comply with all trial procedures and availability for the duration of the trial
- Resident within a pre-defined geographic area to ensure TB clinic follow-up
Age in the registry: 3 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haydom Lutheran Hospital Coordinator of this site? Confirm its status | Haydom | Tanzania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.